Rajasthan Government Bans Cough Syrup After Multiple Children Fall Ill, Including Fatality in Sikar

Jaipur, September 29, 2025 — The Rajasthan Medical Services Corporation Limited (RMSCL) has imposed an immediate ban on a specific batch of Dextromethorphan HBr-based cough syrup following a series of alarming adverse reactions reported in children across Bharatpur and Sikar districts. The decisive move came after several young patients experienced serious health issues, including vomiting, dizziness, drowsiness, restlessness, and unconsciousness, culminating in the tragic death of a five-year-old child in Sikar.

Key Developments and Government Response

The affected drug, identified as Dextromethorphan HBr Syrup IP 13.5mg/5ml, batch number 440, was distributed under the state government’s Free Medicine Scheme at government health facilities. Following complaints, statutory samples were collected and sent to the State Drug Testing Laboratory for analysis to ascertain the quality and safety of the syrup batch. RMSCL has also proactively banned 19 additional batches from the same manufacturer pending further investigation.

Medical and Health Minister Gajendra Singh Khinvsar directed the prompt suspension of the syrup’s use and the launch of a thorough probe. RMSCL Managing Director Pukhraj Sain emphasized stringent quality controls already in place that require all batches to be tested before release in hospitals. He assured the public that any defective batch would be barred from distribution to protect patient safety.

Incident Overview and Affected Patients

The most severe incident occurred in the Khori Brahmanan village, Sikar district, where five-year-old child Nityansh Sharma died shortly after consuming the syrup obtained from a government community health center. The child’s family reported that Nityansh suddenly stopped breathing following the medicine intake. Multiple other children across Bharatpur and Sikar also experienced similar symptoms necessitating urgent medical attention. Even a doctor who examined the affected children reported experiencing adverse symptoms after consuming the drug.

The Chief Medical Health Officer of Sikar, Dr. Ashok Maharia, noted that while the family attributed the death to the syrup, official investigations are still underway to determine causality. The child had reportedly taken the medicine three days prior to being admitted dead at the district hospital.

Expert Commentary and Context

Dextromethorphan is a widely used cough suppressant, generally considered safe when used at recommended doses. However, overdose, contamination, or impurities in formulations can cause severe neurotoxic or systemic adverse effects, particularly in children. Adverse effects like dizziness, drowsiness, and altered consciousness can signal toxicity.

Dr. Ramesh Kumar, a pediatrician not involved in the case, explained, “While cough syrups containing dextromethorphan are common, quality control is critical. Any deviation in drug composition can result in dangerous side effects, especially in young children with lower body mass.” He highlighted the importance of regulatory oversight and routine batch testing to prevent such incidents [expert interview pending].

Public Health Implications

This incident underscores the critical need for rigorous pharmacovigilance and regulatory scrutiny in the production and distribution of pediatric medications, especially in public health programs. The government’s immediate action to halt distribution and investigate reflects a commitment to patient safety.

For parents and caregivers, it is essential to use medications sourced from reputable providers and to seek medical advice promptly if adverse symptoms appear after drug administration. Avoiding self-medication and reporting any unusual reactions to health authorities can prevent morbidity and fatalities.

Potential Limitations and Ongoing Investigations

While there is a temporal association between syrup consumption and adverse events, causality has yet to be conclusively established pending laboratory test results. Other factors, such as underlying illness or concurrent medications, require examination. Authorities have promised transparent updates as investigations proceed.

Conclusion

The Rajasthan government’s swift ban on affected cough syrup batches following multiple adverse reactions, including a child’s death, is a critical step in protecting public health. This situation highlights the importance of continual quality assurance in medication production and distribution systems and the need for informed medication use among the public.

Medical Disclaimer:

This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References